Accelovance is an award-winning, clinical development CRO focused on oncology and immunological vaccine programs across phase I-IV. Accelovance has conducted more than 150 oncology and hematology clinical trials across the globe, spanning a full range of tumor types. The team’s immuno-oncology experience includes immune checkpoint modulators, cellular immunotherapies, oncolytic viruses, peptide vaccines, and bispecific T-cell engagers.
The HERO™ Initiative by Accelovance is a specialized early phase oncology program providing emerging and established biotech and pharmaceutical companies an accelerated means of advancing their early phase cancer compounds through clinical testing. With HERO™, clients benefit from automated technologies and systems, tailored to early phase oncology studies, to expedite trials while keeping costs down.
Additionally, access to the best oncology sites gets you the patients you need, faster and easier than before. Accelovance’s oncology experts work with you to customize your protocol and study design for an optimal outcome. Accelovance provides clients with the scale, expertise, and senior management commitment to maintain immediate and consistent engagement with your team at all times throughout the course of your program, to ensure the successful execution and delivery of your oncology studies